Alembic Pharma rises as its arm gets USFDA’s nod for Diclofenac Sodium Topical Gel

Alembic Pharmaceuticals is currently trading at Rs. 701.80, up by 0.65 points or 0.09% from its previous closing of Rs. 701.15 on the BSE.

The scrip opened at Rs. 701.20 and has touched a high and low of Rs. 707.50 and Rs. 695.25 respectively. So far 4792 shares were traded on the counter.

The BSE group ‘A’ stock of face value Rs. 2 has touched a 52 week high of Rs. 863.10 on 12-Oct-2021 and a 52 week low of Rs. 672.00 on 22-Feb-2022.

alembic pharmaceuticals gets usfda approval for solifenacin succinate tablets
alembic pharmaceuticals gets usfda approval for solifenacin succinate tablets

Last one week high and low of the scrip stood at Rs. 709.90 and Rs. 690.00 respectively. The current market cap of the company is Rs. 13840.99 crore.

The promoters holding in the company stood at 69.61%, while Institutions and Non-Institutions held 18.09% and 12.30% respectively.

Alembic Pharmaceuticals’ wholly owned subsidiary — Aleor Dermaceuticals has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Diclofenac Sodium Topical Gel, 3%.The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD) Solaraze Topical Gel, 3%, of fougera Pharmaceuticals Inc. (Fougera).

Diclofenac Sodium Topical Gel, 3% is indicated for the topical treatment of actinic keratoses. Sun avoidance is indicated during therapy. Diclofenac Sodium Topical Gel, 3% has an estimated market size of. $10 million for twelve months ending March, 2022 according to IQVIA. Alembic has received a cumulative total of 169 ANDA approvals (145 final approvals and 24 tentative approvals) from USFDA.

Alembic Pharmaceuticals, a vertically integrated research and development pharmaceutical company, has been at the forefront of Healthcare since 1907.

Leave a Comment